# Orchestra BioMed Holdings, Inc. (OBIO) · Edgar & Edgarette company card

> Orchestra BioMed Holdings (OBIO) grew revenue 1169% in FY2025 to $33 million, operating margin -155% against a 1.2% median for surgical & medical instruments & apparatus, equity 46.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1814114 · fiscal year ended 2025-12-31 · 4 audited years read · [page](https://www.pops4.com/boards/company/OBIO) · [JSON](https://www.pops4.com/boards/company/OBIO.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $33M |
| Revenue growth, 1 year | 1169.2% |
| Revenue growth per year | 111.6% |
| Operating margin | -154.7% (prior year -2437.5%) |
| Net margin | -157.4% |
| Operating cash flow | −$49M |
| Capital spending | $489,000 |
| Free cash flow | −$49M |
| Cash | $35M |
| Long-term debt | $15M |
| Total assets | $115M |
| Total equity | $54M |
| Equity ÷ assets | 46.6% |
| Return on equity | -98.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -7.02 (distress zone)
- Piotroski F: 6 of 9 (solid)
- Beneish M: 7.04 (above the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -154.7% in FY2025; revenue is hard to predict: its 80% range is ±48%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $33.5M (FY2025), total debt $15.0M. Experience: revenue up 1169.2% on the year, up 111.6% a year over 3 years; operating margin -154.7%, up from -2437.5%. Soundness: equity 46.6% of assets, return on equity -98.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $143.6M and $411.4M next year (method v4.1: its own 2-year record of growth weighed at 25% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $133.6M to $443.3M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -154.7% against a 1.2% median; growth 1169.2% against 11.6%.

Range logged 2026-09-29, receipt aa0e149e2aac4b27, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-02-13 ([filing](https://www.sec.gov/Archives/edgar/data/1814114/000110465926015315/0001104659-26-015315-index.htm))

## Recent filings

- 8-K · filed 2026-10-01 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1814114/000110465926112586/0001104659-26-112586-index.htm)
- 8-K · filed 2026-09-08 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1814114/000110465926105733/0001104659-26-105733-index.htm)
- 10-Q · filed 2026-08-10 · [filing](https://www.sec.gov/Archives/edgar/data/1814114/000110465926093357/0001104659-26-093357-index.htm)
- 8-K · filed 2026-06-23 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1814114/000110465926076845/0001104659-26-076845-index.htm)
- 10-Q · filed 2026-05-12 · [filing](https://www.sec.gov/Archives/edgar/data/1814114/000110465926059382/0001104659-26-059382-index.htm)
- DEF 14A · filed 2026-04-29 · [filing](https://www.sec.gov/Archives/edgar/data/1814114/000110465926051570/0001104659-26-051570-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001814114.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1814114

## Cite

POPS4, Edgar & Edgarette: Orchestra BioMed Holdings, Inc. (OBIO) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/OBIO. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.